

# Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/I5E641576CFEN.html>

Date: April 2021

Pages: 64

Price: US\$ 125.00 (Single User License)

ID: I5E641576CFEN

## Abstracts

Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Incyte Corp (Incyte) is a biopharmaceutical company which discovers, develops and commercializes proprietary cancer therapeutics. The company's lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. Jakafi is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company's pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

### Incyte Corp Key Recent Developments

Feb 09,2021: Incyte reports 2020 fourth quarter and year-end financial results, provides 2021 financial guidance and updates on key clinical programs

Dec 31,2020: Incyte announces data from multiple programs within its oncology portfolio accepted for presentation at the AACR annual meeting 2021

Nov 09,2020: Data from Incyte's Oncology Portfolio accepted for presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting

Nov 05,2020: Incyte reports 2020 third quarter financial results and provides updates on key clinical programs

Aug 04,2020: Incyte reports 2020 second quarter financial results and provides updates on key clinical programs

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Incyte Corp - Key Facts  
Incyte Corp - Key Employees  
Incyte Corp - Key Employee Biographies  
Incyte Corp - Major Products and Services  
Incyte Corp - History  
Incyte Corp - Company Statement  
Incyte Corp - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Incyte Corp - Business Description  
Product Category: Iclusig  
Performance  
Product Category: Jakafi  
Performance  
Product Category: Jakavi Product Royalty Revenue  
Performance  
Product Category: Milestone and Contract Revenue  
Performance  
Product Category: Olumiant Product Royalty Revenue  
Performance  
Product Category: Pemazyre  
Performance  
Product Category: Tavegyl Product Royalty revenue  
Performance  
R&D Overview  
Incyte Corp - Corporate Strategy  
Incyte Corp - SWOT Analysis  
SWOT Analysis - Overview  
Incyte Corp - Strengths  
Incyte Corp - Weaknesses  
Incyte Corp - Opportunities

Incyte Corp - Threats  
Incyte Corp - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Incyte Corp, Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Feb 09, 2021: Incyte reports 2020 fourth quarter and year-end financial results, provides 2021 financial guidance and updates on key clinical programs  
Dec 31, 2020: Incyte announces data from multiple programs within its oncology portfolio accepted for presentation at the AACR annual meeting 2021  
Nov 09, 2020: Data from Incyte’s Oncology Portfolio accepted for presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting  
Nov 05, 2020: Incyte reports 2020 third quarter financial results and provides updates on key clinical programs  
Aug 04, 2020: Incyte reports 2020 second quarter financial results and provides updates on key clinical programs  
Jul 14, 2020: Recently Awarded Project: Incyte 1703  
May 14, 2020: Data from Incyte’s Oncology portfolio accepted for presentation at the ASCO and EHA virtual meetings  
May 05, 2020: Incyte reports 2020 first quarter financial results and provides updates on key clinical programs  
Apr 24, 2020: Incyte appoints Christine Lennon as General Manager, Incyte Biosciences Canada  
Mar 26, 2020: Incyte Names New Member to Its Board of Directors

## **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Incyte Corp, Key Facts  
Incyte Corp, Key Employees  
Incyte Corp, Key Employee Biographies  
Incyte Corp, Major Products and Services  
Incyte Corp, History  
Incyte Corp, Subsidiaries  
Incyte Corp, Key Competitors  
Incyte Corp, Ratios based on current share price  
Incyte Corp, Annual Ratios  
Incyte Corp, Annual Ratios (Cont...1)  
Incyte Corp, Annual Ratios (Cont...2)  
Incyte Corp, Interim Ratios  
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Incyte Corp, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios



## List Of Figures

### LIST OF FIGURES

Incyte Corp, Performance Chart (2016 - 2020)

Incyte Corp, Ratio Charts

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

## I would like to order

Product name: Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/I5E641576CFEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I5E641576CFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970